HYDROS expansion puts PROCEPT BioRobotics in focus

PROCEPT BioRobotics (PRCT) is drawing attention after announcing the international expansion of its HYDROS Robotic System, an AI-enabled Aquablation platform for treating benign prostatic hyperplasia, with the rollout starting in the UK.

The HYDROS rollout news comes after a busy spell for PROCEPT BioRobotics, including the recent board appointment of former Shockwave Medical CFO Daniel Puckett. It lands against a mixed picture where a 7 day share price return of 12.01% contrasts with a 1 year total shareholder return decline of 52.92% and a 3 month share price return decline of 24.85%. This suggests short term momentum is picking up while longer term holders have seen meaningful value erosion.

If HYDROS and AI driven surgery are on your radar, it can also be worth scanning other healthcare focused AI names through our screener of 33 healthcare AI stocks as a way to spot similar themes across the sector.

With HYDROS expanding internationally, shares recovering over the past week, and the stock trading below the average analyst price target, investors are left asking: Is PROCEPT BioRobotics undervalued here, or is the market already pricing in future growth?

Most Popular Narrative: 16.5% Undervalued

With PROCEPT BioRobotics last closing at $27.13 and the most followed fair value estimate sitting at $32.50, the current gap is catching attention and raising questions about what is built into that valuation.

The analyst price target for PROCEPT BioRobotics has been revised from about $50.73 to $32.50 as analysts factor in recent Q4 misses, reduced 2026 guidance, questions around market penetration for Aquablation, and concerns about execution on sales and discounting changes in a competitive BPH market.

Want to see what underpins that reset yet still points to upside? The narrative leans heavily on sustained revenue expansion, improving margins, and a richer multiple than many peers. Curious which assumptions matter most to that $32.50 figure and how sensitive it is to execution on Aquablation and HYDROS adoption? The full story joins those pieces together in a way the headline numbers alone do not.

Result: Fair Value of $32.50 (UNDERVALUED)

However, that upside view can quickly unravel if Aquablation adoption slows or if supply chain dependence on a single Chinese ultrasound supplier starts to bite.

Another View: Multiples Paint A Tougher Picture

The fair value narrative points to upside from $27.13 toward $32.50, yet the current P/S of about 5x tells a different story. That is richer than the US Medical Equipment industry at 2.8x, peers at 3.2x, and even the fair ratio of 3.1x, which suggests less room for error if growth or execution wobbles. Which signal do you trust more when the story gets tested?

Next Steps

Curious whether the cautious tone or the upside case feels closer to reality for you? Take a closer look at the data, weigh both sides, and use 1 key reward and 1 important warning sign to shape your own view today.

Looking for more investment ideas?

If you stop at just one stock, you risk missing out on other opportunities that could fit your style even better, so keep your options wide open.

• Spot potential bargains early by scanning our list of screener containing 26 high quality undiscovered gems before they hit everyone else's radar.
• Build a steadier core to your portfolio by focusing on companies flagged in our 68 resilient stocks with low risk scores that score well on resilience.
• Aim for a stronger income stream by checking companies in our 14 dividend fortresses that pair higher yields with staying power.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.